Thalomid, Thalidomide bms (previously thalidomide celgene)(thalidomide)
Thalomid (thalidomide) is a small molecule pharmaceutical. Thalidomide was first approved as Thalomid on 1998-07-16. It is used to treat aphthous stomatitis, behcet syndrome, crohn disease, discoid lupus erythematosus, and erythema multiforme amongst others in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target protein cereblon.
Download report
Favorite
SARS-CoV-2 Interaction
BMS
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| neoplasms | D009369 |
| musculoskeletal diseases | D009140 |
| digestive system diseases | D004066 |
| stomatognathic diseases | D009057 |
| respiratory tract diseases | D012140 |
| eye diseases | D005128 |
| urogenital diseases | D000091642 |
| cardiovascular diseases | D002318 |
| hemic and lymphatic diseases | D006425 |
Show 4 more
Trade Name
FDA
EMA
Thalomid (generic drugs available since 2023-04-27)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Thalidomide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| THALOMID | Celgene | N-020785 RX | 1998-07-16 | 4 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| thalomid | New Drug Application | 2021-03-11 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| aphthous stomatitis | HP_0011107 | D013281 | K12.0 |
| behcet syndrome | EFO_0003780 | D001528 | M35.2 |
| crohn disease | EFO_0000384 | D003424 | K50 |
| discoid lupus erythematosus | — | D008179 | L93.0 |
| erythema multiforme | — | D004892 | L51 |
| erythema nodosum | HP_0012219 | D004893 | L52 |
| graft vs host disease | — | D006086 | D89.81 |
| langerhans-cell histiocytosis | — | D006646 | C96.6 |
| leprosy | EFO_0001054 | D007918 | A30 |
| multiple myeloma | — | D009101 | C90.0 |
Show 3 more
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Thalidomide, Thalomid, Celgene | |||
| 7230012 | 2023-12-09 | DP | |
HCPCS
No data
Clinical
Clinical Trials
351 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | C90.0 | 12 | 56 | 46 | 3 | 3 | 109 | |
| Non-small-cell lung carcinoma | D002289 | — | 4 | 1 | 1 | — | 5 | ||
| Waldenstrom macroglobulinemia | D008258 | C88.0 | — | 3 | — | 1 | — | 4 | |
| Immunoglobulin light-chain amyloidosis | D000075363 | — | 1 | — | 1 | — | 2 | ||
| Mantle-cell lymphoma | D020522 | C83.1 | — | 1 | — | 1 | — | 2 | |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 1 | — | 1 | — | 2 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | 1 | — | 1 | — | 2 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | — | — | 1 | — | 1 |
| Dermatofibrosarcoma | D018223 | — | — | — | 1 | — | 1 | ||
| Uveitis | D014605 | EFO_1001231 | H20.9 | — | — | — | 1 | — | 1 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Plasma cell neoplasms | D054219 | 1 | 13 | 4 | — | — | 18 | ||
| Neoplasms | D009369 | C80 | 5 | 9 | 2 | — | — | 15 | |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | 9 | 3 | — | 1 | 12 |
| Prostatic neoplasms | D011471 | C61 | 1 | 10 | 1 | — | — | 11 | |
| Myelodysplastic syndromes | D009190 | D46 | — | 7 | 1 | — | 1 | 9 | |
| Lung neoplasms | D008175 | C34.90 | — | 5 | 2 | — | — | 7 | |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | 4 | 1 | — | — | 5 |
| Crohn disease | D003424 | EFO_0000384 | K50 | 1 | 1 | 2 | — | 1 | 5 |
| Colorectal neoplasms | D015179 | — | 3 | 1 | — | — | 4 | ||
| Thalassemia | D013789 | EFO_1001996 | D56 | — | 3 | 1 | — | — | 3 |
Show 16 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 6 | — | — | 3 | 11 |
| Melanoma | D008545 | 2 | 9 | — | — | — | 10 | ||
| Leukemia | D007938 | C95 | 2 | 7 | — | — | 1 | 9 | |
| Central nervous system neoplasms | D016543 | — | 8 | — | — | — | 8 | ||
| Sarcoma | D012509 | — | 6 | — | — | — | 6 | ||
| Lymphoma | D008223 | C85.9 | 1 | 4 | — | — | — | 5 | |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | — | 5 | — | — | — | 5 | |
| Glioblastoma | D005909 | EFO_0000515 | — | 3 | — | — | — | 3 | |
| Graft vs host disease | D006086 | D89.81 | — | 2 | — | — | 1 | 3 | |
| Uveal neoplasms | D014604 | EFO_1001230 | 1 | 3 | — | — | — | 3 |
Show 65 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteosarcoma | D012516 | 1 | — | — | — | — | 1 | ||
| Retinoblastoma | D012175 | 1 | — | — | — | — | 1 | ||
| Ewing sarcoma | D012512 | EFO_0000173 | 1 | — | — | — | — | 1 | |
| Rhabdomyosarcoma | D012208 | 1 | — | — | — | — | 1 | ||
| Primitive neuroectodermal tumors | D018242 | 1 | — | — | — | — | 1 | ||
| Wilms tumor | D009396 | 1 | — | — | — | — | 1 | ||
| Endometriosis | D004715 | EFO_0001065 | N80 | 1 | — | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | 1 | — | — | — | — | 1 |
| Mycobacterium avium-intracellulare infection | D015270 | EFO_0007386 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | — | 1 | 1 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 1 | 1 |
| Hematopoietic stem cell transplantation | D018380 | — | — | — | — | 1 | 1 | ||
| Bone marrow transplantation | D016026 | — | — | — | — | 1 | 1 | ||
| Adrenoleukodystrophy | D000326 | Orphanet_43 | E71.52 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | THALIDOMIDE |
| INN | thalidomide |
| Description | 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione is a dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group. It is a member of piperidones and a member of phthalimides. |
| Classification | Small molecule |
| Drug class | thalidomide derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1 |
Identifiers
| PDB | — |
| CAS-ID | 50-35-1 |
| RxCUI | 10432 |
| ChEMBL ID | CHEMBL468 |
| ChEBI ID | 74947 |
| PubChem CID | 5426 |
| DrugBank | DB01041 |
| UNII ID | 4Z8R6ORS6L (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
Thalomid - Celgene
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 24,311 documents
View more details
Safety
Black-box Warning
Black-box warning for: Thalomid
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
121,431 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more